Join our daily newsletter At The Bell to receive exclusive market insights
- ImpediMed (IPD) has announced AstraZeneca has selected to use another 200 SOZO devices in its phase two trial for chronic kidney disease patients
- The 200 SOZO devices will be leased across 24 countries and is expected to generate around $2 million over the course of 18 months
- This marks the second time AstraZeneca has selected SOZO for its trial after first requesting the devices in September
- In total, 375SOZO devices have been leased under the clinical studies which are expected to bring a total of $4.5 million in revenue
- Company shares are trading 11 per cent higher for 9.1 cents
ImpediMed (IPD) has announced that AstraZeneca has selected SOZO to be used in a phase two trial to measure fluid volume in chronic kidney disease patients.
This marks the second time that AstraZeneca, a global pharmaceutical company, has selected ImpediMed’s SOZO digital health platform for its clinical trial.
Under the contract, ImpediMed will lease 200 SOZO devices across 24 countries which brings the total SOZO devices leased under the studies to 375.
The study is expected to begin in January 2021 and is expected to generate around $2 million over the course of 18 months.
“AstraZeneca’s selection of SOZO for a second clinical trial that is focused on patients with chronic kidney disease provides important validation for our technology and directly aligns with one of our three strategic focus areas,” ImpediMed Managing Director and CEO Richard Carreon said.
The first contract between the two companies was signed in September and saw ImpediMed lease 175 of the CE-Marked devices for the trial which is commencing this month and will span 18 months. Both trials are expected to bring total revenue to $4.5 million.
The AstraZeneca study using SOZO will evaluate the efficacy, safety, and tolerability of a combination of two AstraZeneca drugs in patients with chronic kidney disease.
Nearly 750,000 patients per year in the U.S. and an estimated two million patients worldwide are affected by end-stage renal disease (ESRD). Those who live with ESRD are 1 per cent of the U.S. Medicare population but account for 7 per cent of the Medicare budget, or around US$35 billion (roughly A$48 billion).
Company shares are trading 11 per cent higher for 9.1 cents at 2:39 pm AEDT.
